Impax Laboratories has entered into a supply agreement with Resolution Chemicals to receive finished Dronabinol product. The company also reported that it has acquired Abbreviated New Drug Applications (ANDA) from Watson Pharmaceuticals and Cobalt Laboratories, a subsidiary of Arrow Group.
In connection with Watson’s acquisition of Arrow Group, Impax acquired from Watson its ANDA for Cabergoline, the generic equivalent to Dostinex.
Impax has also acquired its pending ANDA for Dronabinol, the generic equivalent to Marinol from Cobalt Pharmaceuticals.
Larry Hsu, president and chief executive officer of Impax Laboratories, said: “The acquisition of these ANDAs is consistent with our strategic and longer term generic growth initiatives to identify external opportunities to expand our base business.
“The growth initiatives include evaluating the potential to expand beyond solid oral dosage forms as well as into markets beyond current US footprint. In addition, we will be open to opportunities to in-license products, as well as potential product or company acquisitions that will drive long-term profitable growth.”